Genetic Technologies
Genetic Technologies Inks US Commercialization Deal for COVID-19 Risk Test With Infinity Biologix
The test is designed to assess the risk of a person developing severe disease if they contract COVID-19 based on a combination of genetic and clinical factors.
Genetic Technologies to Raise $6.6M in Direct Offering
The company said it had signed definitive agreements to sell $6.6 million of its American Depository Shares to undisclosed institutional investors.
Genetic Technologies Lands Distribution Rights to Taliaz Antidepressant Drug Selection Tools
The products analyze various datasets including a patient's genetic and metabolic profiles, clinical history, and demographics to inform prescribing decisions.
Genetic Technologies Regains Compliance With Rules for Nasdaq Listing
The Australian molecular diagnostics firm had stockholders' equity in excess of $2.5 million as of Aug. 28, in compliance with the Nasdaq listing rule.
Genetic Technologies to Raise $5.1M in Direct Offering
The Australian molecular diagnostics firm said it has signed agreements sell 1,025,000 of its American Depository Shares to several institutional investors.